Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion

Inclusion Criteria: * Patients 2 - 18 years of age * Patients with a diagnosis of moderate to severe atopic dermatitis, assessed by a score ≥ 3 at the Investigator's Global Assessment. AD to involve at least 30% of their body surface area as determined by the rule of nine or the Lund and Browder chart. Exclusion Criteria: * Erythrodermic patients with Netherton's syndrome * Patients with known serious adverse reactions or hypersensitivity to any of the excipients of the study medication * Patients with a history of cancer, skin malignancy or lymphoproliferative disorders or of immunocompromise, including a positive HIV (ELISA and Western blot), Hepatitis B surface antigen (HBsAg) or Hepatitis C test result Other protocol-defined inclusion/exclusion criteria may apply